Zinger Key Points
- Plus Therapeutics shares are trading higher by 244% during Thursday's session.
- The company announced that the FDA accepted the name REYOBIQ for the company's lead asset.
- Feel unsure about the market’s next move? Copy trade alerts from Matt Maley—a Wall Street veteran who consistently finds profits in volatile markets. Claim your 7-Day free trial now.
Plus Therapeutics Inc PSTV shares are trading higher by 244% to $1.75 during Thursday’s session after the company announced that the FDA accepted the name REYOBIQ for the company’s lead asset.
What To Know: Plus Therapeutics, a clinical-stage pharmaceutical company developing targeted radiotherapeutics for central nervous system cancers, announced that the U.S. Food and Drug Administration has conditionally accepted the proprietary name REYOBIQ for its lead therapeutic candidate.
The name will officially be reviewed once the company submits its marketing application. Moving forward, all references to the generic name rhenium Re186 obisbemeda will use the REYOBIQ branding.
Read Also: Trump Urges Fed To Cut Interest Rates As ‘Liberation Day In America’ Looms
What Else: Russ Havranek, VP of Corporate Strategy and New Product Planning, emphasized that branding plays a crucial role in commercialization, helping stakeholders—including investigators, investors and patients—connect with the treatment beyond its chemical identity.
The company says it aims to build awareness of the REYOBIQ name and logo, reinforcing its progress in developing targeted radiotherapeutics for leptomeningeal metastases and glioblastoma multiforme.
How To Buy PSTV Stock
By now you're likely curious about how to participate in the market for Plus Therapeutics – be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy “fractional shares,” which allows you to own portions of stock without buying an entire share.
In the case of Plus Therapeutics, which is trading at $1.48 as of publishing time, $100 would buy you 67.57 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to “go short” a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.
According to data from Benzinga Pro, PSTV has a 52-week high of $2.67 and a 52-week low of $0.24.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.